BridgeMD
New treatment option for ADHD - Attention Deficit Disorder With Hyperactivity
Official title Medication Treatment of ADHD in Pediatric Epilepsy
ClinicalTrials.gov ID: NCT07594652
What this study is testing
What is methylphenidate hydrochloride (Jornay PM)?
methylphenidate hydrochloride (Jornay PM) is an investigational medicine, being studied as a potential treatment for adhd - attention deficit disorder with hyperactivity.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 17
You may be able to join if
- Established diagnosis of epilepsy that requires treatment with anti-seizure medication.
- No episodes of seizure clusters or status epilepticus within 30 days prior to entry into the study.
- Diagnosis of ADHD with functional impairment.
- Good general health as determined by medical history and physical examination, including stable vital signs.
- Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance...
You likely can't join if
- Previous allergic or hypersensitivity reactions to stimulant medicines including Jornay PM®
- Active substance abuse or dependence within 30 days of enrollment
- Epilepsy that is unstable or with seizure frequency that exceeds four events per month, based on an average over the previous three months
- DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.
- Current use of stimulants to treat ADHD
- Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes.
See the full eligibility criteria
- Established diagnosis of epilepsy that requires treatment with anti-seizure medication.
- No episodes of seizure clusters or status epilepticus within 30 days prior to entry into the study.
- Diagnosis of ADHD with functional impairment.
- Good general health as determined by medical history and physical examination, including stable vital signs.
- Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.
- Previous allergic or hypersensitivity reactions to stimulant medicines including Jornay PM®
- Active substance abuse or dependence within 30 days of enrollment
- Epilepsy that is unstable or with seizure frequency that exceeds four events per month, based on an average over the previous three months
- DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.
- Current use of stimulants to treat ADHD
- Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes.
- Unstable cardiac illness such as arrythmias or cardiomyopathy.
- Participation in a previous experimental drug study within 30 days of baseline visit.
- Estimated IQ\<70 as indicated by clinical assessment to the degree that rating scales may be invalid
- Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures
The study team makes the final eligibility decision.
Where it's taking place
- Baltimore, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baltimore, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.